Financial Solutions Advisory Group Inc. Acquires New Shares in Boston Scientific Corporation $BSX

Key Points

• Financial Solutions Advisory Group acquired 25,293 Boston Scientific shares in the third quarter, valued at approximately $1.12 million. Other institutions also increased their positions, with institutional investors collectively owning 89.07% of the company.
• Boston Scientific reported quarterly revenue of $5.14 billion and adjusted EPS of $0.73, matching earnings expectations while exceeding revenue estimates. However, management lowered full-year adjusted EPS guidance and cited cybersecurity disruption, pricing pressure and weakness in some product areas.
• Analyst sentiment remains broadly positive but has become more cautious: the stock carries a “Moderate Buy” consensus rating with an average price target of $61.87, while several firms recently cut targets or downgraded their ratings.

Financial Solutions Advisory Group Inc. acquired a new stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 25,293 shares of the medical equipment provider's stock, valued at approximately $1,123,000.

A number of other institutional investors have also recently bought and sold shares of BSX. Choreo LLC boosted its position in shares of Boston Scientific by 12.8% during the third quarter. Choreo LLC now owns 43,410 shares of the medical equipment provider's stock worth $1,895,000 after purchasing an additional 4,937 shares in the last quarter. Interchange Capital Partners LLC bought a new stake in shares of Boston Scientific in the 3rd quarter valued at $209,000. China Universal Asset Management Co. Ltd. increased its position in shares of Boston Scientific by 60.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 20,000 shares of the medical equipment provider's stock valued at $878,000 after buying an additional 7,500 shares in the last quarter. D.A. Davidson & CO. raised its stake in Boston Scientific by 7.6% during the 3rd quarter. D.A. Davidson & CO. now owns 35,065 shares of the medical equipment provider's stock worth $1,531,000 after buying an additional 2,463 shares during the period. Finally, Pinnacle Wealth Planning Services Inc. raised its stake in Boston Scientific by 58.3% during the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 14,047 shares of the medical equipment provider's stock worth $613,000 after buying an additional 5,172 shares during the period. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Trading Up 0.6%

BSX opened at $42.69 on Friday. The stock has a market capitalization of $61.86 billion, a P/E ratio of 18.09, a P/E/G ratio of 1.04 and a beta of 0.58. Boston Scientific Corporation has a 12 month low of $39.57 and a 12 month high of $105.65. The firm's fifty day simple moving average is $44.93 and its 200 day simple moving average is $57.15. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, hitting analysts' consensus estimates of $0.73. The firm had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. Boston Scientific had a net margin of 16.62% and a return on equity of 18.73%. The company's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.75 EPS. As a group, research analysts anticipate that Boston Scientific Corporation will post 3.18 EPS for the current fiscal year.

Insider Activity

In other news, Director David Habiger acquired 2,100 shares of the firm's stock in a transaction that occurred on Wednesday, August 5th. The stock was acquired at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the acquisition, the director owned 17,160 shares in the company, valued at $816,644.40. This represents a 13.94% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Michael Mahoney bought 186,240 shares of the company's stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the transaction, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. The trade was a 13.27% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought 189,522 shares of company stock valued at $9,157,810 over the last ninety days. 0.34% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research analysts have weighed in on BSX shares. Truist Financial reduced their target price on Boston Scientific from $57.00 to $51.00 and set a "buy" rating on the stock in a report on Wednesday, October 14th. Piper Sandler lowered their price target on Boston Scientific from $65.00 to $60.00 and set an "overweight" rating for the company in a report on Wednesday, July 29th. Needham & Company LLC dropped their price target on Boston Scientific from $57.00 to $48.00 and set a "buy" rating on the stock in a research report on Wednesday. Weiss Ratings reiterated a "sell (d+)" rating on shares of Boston Scientific in a report on Friday, October 2nd. Finally, Wall Street Zen lowered Boston Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, August 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of "Moderate Buy" and an average price target of $61.87.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Third-quarter revenue increased 1.5% year over year to $5.138 billion, topping the $5.07 billion consensus estimate, while adjusted earnings of $0.73 per share matched expectations. Boston Scientific announces results for third quarter 2026
• Positive Sentiment: Robert W. Baird raised its price target from $50 to $51 and maintained an “outperform” rating, while BTIG, UBS and Sanford C. Bernstein retained bullish ratings despite lowering their targets. Analysts revise forecasts after Q3 results
• Positive Sentiment: Management pointed to long-term growth initiatives, including Elite AF trial enrollment and FDA clearances for StoneSmart and SEISMIQ catheter technologies. Recent insider activity also showed purchases rather than sales, offering a modest confidence signal.
• Neutral Sentiment: Boston Scientific expects approximately 4.25% reported full-year 2026 sales growth, but forecast fourth-quarter reported and organic sales declines of 1% to 3%. Boston Scientific cuts view again after cyberattack
• Negative Sentiment: An eight-day cybersecurity outage reduced third-quarter sales by roughly $150 million and continues to affect operations, customer activity and the recovery timeline.
• Negative Sentiment: Management lowered full-year adjusted EPS guidance to $3.16-$3.18, below investor expectations, and warned that growth could remain broadly flat in 2027 as EP and WATCHMAN weakness, China pricing pressure and product-related challenges persist. BSX Q3 earnings call flags growth challenges
• Negative Sentiment: Analyst sentiment became more cautious: Oppenheimer downgraded BSX to “market perform,” JPMorgan moved to “neutral,” and multiple firms cut price targets, including Wells Fargo to $45 and Needham to $48.

Boston Scientific Company Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.